Therapeutic potential of new hydrogen sulfide-releasing hybrids

References

• Kajimur M, Fukuda R, Bateman RM, Yamamoto T, Suematsu M. Interactions of multiple gas-transducing systems: hallmarks and uncertainties of CO, NO and H2S gas biology. Antioxid. Redox Signal.13(2), 157–192 (2010).
   PubMedGoogle Scholar
• Wang R. Toxic gas, lifesaver. Sci. Am.302(3), 66–71 (2010).
   PubMedGoogle Scholar
• Li L, Hsu A, Moore PK. Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide and inflammation – a tale of three gases! Pharmacol. Ther.123(3), 386–400 (2009).
   PubMed Web of Science ®Google Scholar
• Olson KR, Donald JA. Nervous control of circulation – the role of gasotransmitters, NO, CO, and H2S. Acta Histochem.111(3), 244–256 (2009).
   PubMedGoogle Scholar
• Turnbull CM, Rossi, AG, Megson IL. Therapeutic effects of nitric oxide-aspirin hybrid drugs. Expert Opin. Ther. Targets10(6), 911–922 (2006).
   PubMed Web of Science ®Google Scholar
• Burgaud JL, Ongini E, Del Soldato P. Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic agents. Ann. NY Acad. Sci.962, 360–371 (2002).
   PubMed Web of Science ®Google Scholar
• Li L, Moore PK. Putative biological roles of hydrogen sulphide in health and disease: a breath of not so fresh air? Trends Pharmacol. Sci.29(2), 84–90 (2008).
   PubMed Web of Science ®Google Scholar
• Cooper CE, Brown GC. The inhibition of mitochondrial cytochrome oxidase by the gases carbon monoxide, nitric oxide, hydrogen cyanide and hydrogen sulphide: chemical mechanism and physiological significance. J. Bioenerg. Biomembr.40(5), 533–539 (2008).
   PubMed Web of Science ®Google Scholar
• Goubern M, Andriamihaja M, Nubel T, Blachier F, Bouillaud F. Sulfide, the first inorganic substrate for human cells. FASEB J.21(8), 1699–1706 (2007).
   PubMed Web of Science ®Google Scholar
• Abu-Mohamed G, Johnson JA, EL-Remessy AB et al. Role of superoxide, peroxynitrite, and protein kinase C in the development of tolerance to nitroglycerin. J. Pharmacol. Exp. Ther.308(1), 289–299 (2004).
   PubMedGoogle Scholar
• Grosser N, Schroeder H. A common pathway for nitric oxide release from NO-aspirin and glyceryl trinitrate. Biochem. Biophys. Res. Commun.274(1), 255–258 (2000).
   PubMed Web of Science ®Google Scholar
• Lee DH, Pfeifer GP. Mutagenesis induced by the nitric oxide donor sodium nitroprusside in mouse cells. Mutagenesis22(1), 63–67 (2007).
   PubMed Web of Science ®Google Scholar
• Li L, Rossoni G, Sparatore A, Lee LC, Del Soldato P, Moore PK. Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic. Biol. Med.42(5), 706–719 (2007).
   PubMed Web of Science ®Google Scholar
• Giustarini D, Del Soldato P, Sparatore A, Rossi R. Modulation of thiol homeostasis induced by H2S-releasing aspirin. Free Radic. Biol. Med.48(9), 1263–1272 (2010).
   PubMed Web of Science ®Google Scholar
• Giustarini D, Perrino E, Tazzari V, Rossi R. HPLC determination of novel dithiolethione containing drugs and its application for in vivo studies in rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.878(3–4), 340–346 (2009).
   PubMedGoogle Scholar
• Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL. Glutathione dysregulation and the etiology and progression of human diseases. Biol. Chem.390(3), 191–214 (2009).
   PubMed Web of Science ®Google Scholar
• Finkelstein JD. Pathways and regulation of homocysteine metabolism in mammals. Semin. Thromb. Hemost.26(3), 219–225 (2000).
   PubMed Web of Science ®Google Scholar
• Mosharov E, Cranford MR, Banerjee R. The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. Biochemistry39(42), 13005–13011 (2000).
   PubMed Web of Science ®Google Scholar
• Chiku T, Padovani D, Zhu W, Singh S, Vitvitsky V, Banerjee R. H2S biogenesis by human cystathionine γ-lyase leads to the novel sulfur metabolites lanthionine and homolanthionine and is responsive to the grade of hyperhomocysteinemia. J. Biol. Chem.284(17), 11601–11612 (2009).
   PubMed Web of Science ®Google Scholar
• Szabò C. Hydrogen sulphide and its therapeutic potential. Nat. Rev. Drug Discov.6(11), 917–935 (2007).
   PubMed Web of Science ®Google Scholar
• Kimura Y, Goto Y, Kimura H. Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. Antioxid. Redox Signal.12(1), 1–13 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Munday R. Dithiolethiones for cancer chemoprevention: where do we stand? Mol. Cancer Ther.7(11), 3470–3479 (2008).
   PubMed Web of Science ®Google Scholar
• Ansher SS, Dolan P, Buending E. Biochemical effects of dithiolthiones. Food Chem. Toxicol.24(5), 405–415 (1986).
   PubMed Web of Science ®Google Scholar
• Meunier B. Hybrid molecules with a dual mode of action: dream or reality? Acc. Chem. Res.41(1), 69–77 (2008).
   PubMed Web of Science ®Google Scholar
• Viegas-Junior C, Danuello A, Da Silva Bolzani V, Barreiro EJ, Manssour Fraga CA. Molecular hybridization: a useful tool in the design of new drug prototypes. Curr. Med. Chem.14, 1829–1852 (2007).
   PubMed Web of Science ®Google Scholar
• Sidhapuriwala J, Li L, Sparatore A, Bhatia M, Moore PK. Effect of S-diclofenac, a novel hydrogen sulfide releasing derivative, on carrageenan-induced hindpaw oedema formation in the rat. Eur. J. Pharmacol.569(1–2), 149–154 (2007).
   PubMed Web of Science ®Google Scholar
• Wallace JL, Caliendo G, Santagata V, Cirino G, Fiorucci S. Gastrointestinal safety and antinflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology132(1), 261–271 (2007).
   PubMed Web of Science ®Google Scholar
• Bhatia M, Sidhapuriwala JN, Sparatore A, Moore PK. Treatment with H2S-releasing diclofenac protects mice against acute pancreatitis-associated lung injury. Shock29(1), 84–88 (2008).
   PubMed Web of Science ®Google Scholar
• Rossoni G, Sparatore A, Tazzari V, Manfredi B, Del Soladato P, Berti F. The hydrogen sulfide-releasing derivative of diclofenac protects against ischaemia–reperfusion injury in the isolated rabbit heart. Br. J. Pharmacol.153(1), 100–109 (2008).
   PubMed Web of Science ®Google Scholar
• Conforti A, Donini M, Brocco G, Del Soldato P, Benoni P, Cuzzolin L. Acute antiinflammatory activity and gastrointestinal tolerability of diclofenac and nitrofenac. Agents Actions40(3–4), 176–180 (1993).
   PubMedGoogle Scholar
• Cuzzolin L, Conforti A, Donini M, Adami A, Del Soldato P, Benoni G. Effects on intestinal microflora, gastrointestinal tolerability and antiinflammatory efficacy of diclofenac and nitrofenac in adjuvant arthritic rats. Pharmacol. Res.29(1), 89–97 (1994).
   PubMedGoogle Scholar
• Isenberg JS, Jia Y, Field L, et al. Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid. Br. J. Pharmacol.151(1), 63–72 (2007).
   PubMed Web of Science ®Google Scholar
• Reuter S, Gupta SC, Chaturvedi MM, Bharat BA. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic. Biol. Med. DOI: 10.1016/j.freeradbiomed.2010.09.006 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Papapetropoulos A, Pyriochou A, Altaany Z et al. Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc. Natl Acad. Sci. USA106(51), 21972–21977 (2009).
   PubMed Web of Science ®Google Scholar
• Baskar R, Sparatore A, Del Soldato P, Moore PK. Effect of S-diclofenac, a novel hydrogen sulfide releasing derivative inhibit rat vascular smooth muscle cell proliferation. Eur. J. Pharmacol.594(1–3), 1–8 (2008).
   PubMed Web of Science ®Google Scholar
• Idris AI, Frantzias J, Sparatore A, Del Soldato P, Ralston SH. Identification of hydrogen sulfide releasing compounds as novel antiresorptive and antitumour agents. Presented at: 10th International Conference on Cancer-Induced Bone Disease. Sheffield, UK, 22–25 September 2010.
   Google Scholar
• Wallace JL. Hydrogen sulfide-releasing anti-inflammatory drugs. Trends Pharmacol. Sci.28(10), 501–505 (2007).
   PubMed Web of Science ®Google Scholar
• Wallace JL, Caliendo G, Santagada V, Cirino G. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br. J. Pharmacol.159(6), 1236–1246 (2010).
   PubMed Web of Science ®Google Scholar
• Rosenthal D, Taylor TI. Mechanism and kinetics of the thioacetamide hydrolysis reaction. JACS79, 2684–2690 (1957).
   Google Scholar
• Taurog A. Hormone synthesis: tyroid iodine methabolism. In: Werner and Ingbar’s The Thyroid: A Fundamental and Clinical Text (8th Edition). Braverman LE, Utiger RD (Eds). Lippincott Williams & Wilkins, PA, USA 61–84 (2000).
   Google Scholar
• Taurog A. The mechanism of action of the thioureylene antithyroid drugs. Endocrinology98, 1031–1046 (1976).
   PubMed Web of Science ®Google Scholar
• Ikehata K, Duzhak TG, Galeva NA, Ji T, Koen YM, Hanzlik RP. Protein targets of reactive metabolites of thiobenzamide in rat liver in vivo. Chem. Res. Toxicol.21(7), 1432–1442 (2008).
   PubMed Web of Science ®Google Scholar
• Warnet JM, Christen MO, Thevenin M, Briard D, Jaqueson A, Claude JR. Protective effect of anethole dithiolthione against acetaminophen hepathotoxicity in mice. Pharmacol. Toxicol.65(1), 63–64 (1989).
   PubMedGoogle Scholar
• Christen MO. Anethole dithiolethione: biochemical considerations. Meth. Enzymol.252, 316–323 (1995).
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Orlandi S, Mencarelli A et al. Enhanced activity of a hydrogen sulphide releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br. J. Pharmacol.150, 996–1002 (2007).
   PubMed Web of Science ®Google Scholar
• Distrutti E, Sediari L, Mencarelli A et al. 5-amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J. Pharmacol. Exp. Ther.319(1), 259–271 (2006).
   Google Scholar
• Del Soldato P, Sorrentino R, Pinto, A. NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol. Sci.20, 319–323 (1999).
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Antonelli E, Santucci LA. Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology116, 1089–1106 (1999).
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Santucci L, Gresele P, Maffei-Facino R, Del Soldato P, Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology124, 600–607 (2003).
   PubMed Web of Science ®Google Scholar
• Sparatore A, Perrino E, Tazzari V et al. Pharmacological profile of a novel H2S-releasing aspirin. Free Radic. Biol. Med.46(5), 586–592 (2008).
   PubMedGoogle Scholar
• Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia. Annu. Rev. Med.60, 39–54 (2009).
   PubMed Web of Science ®Google Scholar
• Ciaccio M, Bellia C. Hyperhomocysteinemia and cardiovascular risk: effect of vitamin supplementation in risk reduction. Curr. Clin. Pharmacol.5(1), 30–36 (2010).
   PubMedGoogle Scholar
• Martí-Carvajal AJ, Solà I, Lathyris D, Salanti G. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst. Rev. (4), CD006612 (2009).
   PubMedGoogle Scholar
• Loscalzo J. Homocysteine trials: clear outcomes for complex reasons. N. Engl. J. Med.354 (15), 1629–1632 (2006).
   PubMed Web of Science ®Google Scholar
• Urquhart BL, Freeman DJ, Spence JD, House AA. Mesna as a nonvitamin intervention to lower plasma total homocysteine concentration: implications for assessment of the homocysteine theory of atherosclerosis. J. Clin. Pharmacol.47(8), 991–997 (2007).
   PubMedGoogle Scholar
• Giral P, Jacob N, Dourmap C et al. Elevated γ-glutamyltransferase activity and perturbed thiol profile are associated with features of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol.28(3), 587–593 (2008).
   PubMedGoogle Scholar
• Rossoni G, Manfredi B, Tazzari V et al. Activity of a new hydrogen sulfide-releasing aspirin (ACS14) on pathological cardiovascular alterations induced by glutathione depletion in rats. Eur. J. Pharmacol.648(1–3), 139–145 (2010).
   PubMedGoogle Scholar
• Shukla N, Rossoni G, Hotston M et al. Effect of hydrogen sulphide-donating sildenafil (ACS6) on erectile function and oxidative stress in rabbit isolated corpus cavernosum and in hypertensive rats. BJU Int.103(11), 1522–1529 (2009).
   PubMed Web of Science ®Google Scholar
• Lau DH, Kommu S, Mumtaz FH, Morgan RJ, Thompson CS, Mikhailidis DP. The management of phosphodiesterase-5 (PDE5) inhibitor failure. Curr. Vasc. Pharmacol.4, 89–93 (2006).
   PubMedGoogle Scholar
• Muzaffar S, Jeremy JY, Sparatore A, Del Soldato P, Angelini GD, Shukla N. H2S-donating sildenafil (ACS6) inhibits superoxide formation and gp91phox expression in arterial endothelial cells: role of protein kinases A and G. Br. J. Pharmacol.155(7), 984–994 (2008).
   PubMedGoogle Scholar
• Kimura Y, Kimura H. Hydrogen sulphide protects neurons from oxidative stress. FASEB J.18(10), 1165–1167 (2004).
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG. Local neuroinflammation and the progression of Alzheimer’s disease. J. Neurovirol.8(6), 529–538 (2002).
   PubMed Web of Science ®Google Scholar
• Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson’s disease. Br. J. Pharmacol.150(8), 963–976 (2007).
   PubMed Web of Science ®Google Scholar
• Lee M, Sparatore A, Del Soldato P, McGeer E, McGeer PL. Hydrogen sulfide-releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation. Glia58(1), 103–113 (2010).
   PubMed Web of Science ®Google Scholar
• Lee M, Tazzari V, Giustarini D et al. Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: potential for treating Parkinson disease. J. Biol. Chem.285(23), 17318–17328 (2010).
   PubMed Web of Science ®Google Scholar
• Benavides GA, Squadrito GL, Mills RW. Hydrogen sulfide mediates the vasoactivity of garlic. Proc. Natl Acad. Sci. USA104(46), 17977–17982 (2007).
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hyman L, Bengtsson B, Yang Z; EMGT Group. Predictors of long term progression in the early manifest glaucoma trial. Ophtalmology114(11), 1965–1972 (2007)
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ, Gordon MO, Beiser JA et al; Ocular Hypertension Treatment Study Group. The ocular hypertension treatment study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch. Ophthalmol.122(6), 813–820 (2004).
   PubMed Web of Science ®Google Scholar
• McKinnon SJ, Goldberg LD, Peeples P, Walt JG, Bramley TJ. Current management of glaucoma and the need for complete therapy. Am. J. Manag. Care14(1 Suppl.), S20–S27 (2008).
   PubMedGoogle Scholar
• Osborne NN, Ji D, Abdul Majid AS, Fawcett RJ, Sparatore A, Del Soldato P. ACS67, a hydrogen sulfide-releasing derivative of latanoprost acid, attenuates retinal ischemia and oxidative stress to RGC-5 cells in culture. Invest. Ophthalmol. Vis. Sci.51, 284–294 (2010).
   PubMedGoogle Scholar
• Perrino E, Uliva C, Lanzi C, Del Soldato P, Masini E, Sparatore A. New prostaglandin derivative for glaucoma treatment. Bioorg. Med. Chem. Lett.19(6), 1639–1642 (2009).
   PubMed Web of Science ®Google Scholar